3D-PharmXchange congratulates MimeCure on raising €3 million to accelerate the development of its therapy for chronic lung diseases, including Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD). The investment round is led by Addington Investment Group, with Apsara Investments as co-investor. The funds will support MimeCure in completing the preclinical phase and preparing for first-in-human clinical studies.
MimeCure
MimeCure is a Dutch biotechnology company developing regenerative therapies for chronic lung diseases. The company is a spin-out from the Rijksuniversiteit Groningen, where the scientific foundation for the technology was established through research conducted at the Groningen Research Institute of Pharmacy.
MimeCure is developing MC002 as an inhaled therapy intended to deliver the active substance directly to the lungs. The therapeutic concept is designed to combine two complementary effects within a single treatment approach: reducing scar tissue formation and activating the lung’s natural tissue repair capacity. Through this dual mechanism, MC002 aims to target fundamental processes involved in tissue damage and regeneration, with potential relevance across multiple fibrotic lung diseases.
Medical need
Idiopathic Pulmonary Fibrosis is a progressive fibrotic lung disease in which healthy lung tissue is gradually replaced by scar tissue. This leads to increasing stiffness of the lungs, impaired gas exchange and symptoms such as breathlessness, cough and reduced exercise capacity. IPF is associated with a poor prognosis; untreated patients have a reported median survival of approximately three years.
The disease affects an estimated 2.5 million people worldwide. Despite currently available antifibrotic therapies, treatment remains limited to slowing disease progression rather than restoring damaged lung tissue. This leaves a clear need for novel therapeutic approaches that address the underlying tissue injury and loss of lung function.
Bespoke drug development support to MimeCure
3D-PharmXchange is proud to provide integrated drug development support to MimeCure as MC002 progresses toward clinical readiness, contributing expertise across CMC, non-clinical development and regulatory affairs. The work is structured to support harmonized advancement of the program toward IND readiness and, ultimately, first-in-human evaluation.
Read the full announcement from MimeCure at this link.
